OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that an abstract on its lead candidate, urcosimod, has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
The abstract, titled “Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study”, will be presented in the Ocular Surface Disease II session on April 11, 2026, in Washington, DC.
Royalty Management Holding Corp (NASDAQ:RMCO) said it has set March 31, 2026, as the record date for its next quarterly cash dividend.
Shareholders on that date will receive a dividend of $0.0025 per share, payable on April 10, 2026.
NEXE Innovations Inc (TSX-V:NEXE, OTC:NEXNF, FRA:FRA: NX5) reported higher revenue and improved cost controls in its second quarter of fiscal 2026, while outlining plans to accelerate commercialization through partnerships and licensing initiatives.
For the three months ended November 30, 2025, the maker of compostable materials and products reported revenue of about $199,000 up from about $71,000 in the same quarter a year earlier. The increase was attributed to the continued uptake of its compostable coffee pod, launched in late 2024, and the addition of a customer targeting the big-box retail channel.
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agency’s human medicines committee has issued a positive opinion recommending approval of an expanded dosing regimen for Elfabrio, its treatment for Fabry disease, in adult patients.
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a 2 mg/kg every-four-weeks dosing schedule for Elfabrio in adult Fabry patients who are stable on enzyme replacement therapy, following a re-examination of the application.
Delivra Health Brands Inc. (TSX-V:DHB, OTCQB:DHBUF, FRA:3F0) said on Friday it has appointed John Barrett as a director, adding a former senior executive from major consumer goods companies as the health and wellness products maker looks to its next phase of growth.
Barrett previously held senior roles at Frito-Lay and PepsiCo and served as chief commercial officer for Pernod Ricard USA. He is currently owner and principal consultant at Kites Advisors, a boutique firm that works with early-stage consumer goods companies on strategy across the value chain.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has strengthened its management team, appointing Helge Weiner-Trapness as its new chief strategy officer and executive director.
The newly created role will support the company’s long-term international growth strategy. His responsibilities include corporate development, partnership strategy, and portfolio prioritisation.
London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) announced it has signed a 30-day exclusive call option to acquire a 100% interest in the tenements containing the historic Chance gold mine, in Western Australia.
The company said the move forms “Stage One” of a hedging strategy aimed at reducing exposure to Bitcoin volatility, and, follows comments made in its interim results published in November.
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) on Friday gave investors a project update, across both its UK and US portfolio, and highlighted that a programme focussed on costs and efficiencies is expected to deliver improved net cash flow.
In the UK, the company said its Wressle field in Lincolnshire remains one of the most productive conventional oilfields in the country. Average gross production during January 2026 was about 267 barrels of oil per day (on full production days, the range is between 267 and 339 bopd).
AuMEGA Metals Ltd (ASX:AAM, TSX:AUM, OTCQB:AUMMF, FRA:FRA: MA30) has released its quarterly activities report for the period ended 31 December 2025, outlining exploration progress and target generation across its district-scale landholding in Newfoundland and Labrador, Canada. All amounts are in Canadian dollars unless otherwise stated.
AuMEGA's non-executive chair Justin Osborne spoke with Proactive last week about the company’s focused exploration strategy in Newfoundland, Canada, where it controls about 110 kilometres of tenure along the highly prospective Cape Ray–Valentine Shear Zone. The structural corridor also hosts Equinox Gold’s 5Moz Valentine Gold Project, which has recently entered commercial production.
Recce Pharmaceuticals Ltd has reported solid operational momentum in its December 2025 quarter, highlighted by continued progress in its registrational Phase 3 clinical trial for diabetic foot infections (DFI) in Indonesia and encouraging new preclinical data for inhaled RECCE® 327 in hospital-acquired pneumonia models.
The company also strengthened its intellectual property position with a new Hong Kong patent grant and secured meaningful non-dilutive funding support through Australia’s R&D tax incentive framework.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) advanced both its hydrogen shipping and CO₂ storage programs during the December 2025 quarter, strengthening commercial partnerships and progressing key technical milestones ahead of planned 2026 readiness.
The company said the quarter delivered tangible progress across its compressed hydrogen (H₂) and liquid CO₂ (LCO₂) platforms, underpinned by deeper engagement with strategic partners and resumed fabrication activity at its Norwegian robotics facility.
Cobalt Blue Holdings Ltd (ASX:COB, OTC:CBBHF, FRA:COH) says progress towards a final investment decision (FID) on its proposed Kwinana Cobalt Refinery (KCR) remained the central focus of a busy December 2025 quarter, as the company refreshed project economics, advanced offtake and financing discussions and strengthened its funding position with an oversubscribed capital raise.
Cobalt Blue told investors it completed a re-evaluation of KCR project parameters in response to structural changes in global cobalt markets during 2025. The updated approach narrows feedstock assumptions to cobalt hydroxide, expands the product mix to include cobalt metal alongside cobalt sulphate, and refreshes underlying economic assumptions ahead of FID.
Kairos Minerals Ltd (ASX:KAI, OTCQB:KAIFF, FRA:YAJ) has wrapped up its largest drilling program to date at the Mt York Gold Project in Western Australia, setting the stage for an updated mineral resource estimate (MRE) expected in the first half of calendar 2026.
The December 2025 quarter marked the completion of a 2025 drill campaign spanning the full 4.5-kilometre strike length of the Mt York gold system, with 128 reverse circulation and diamond holes drilled for 26,971 metres. The program was finalised ahead of the Pilbara summer and focused heavily on extending mineralisation at Main Hill, Gossan Hill and Breccia Hill.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) reported further positive clinical results during the December 2025 quarter, with its azer-cel Phase 1b trial achieving an Overall Response Rate of 82% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Of the 17 evaluable patients treated, 14 responded to therapy, including seven complete responses and seven partial responses. The company said responses were rapid, with best responses typically observed within one to three months, and noted that the first patient dosed in 2024 remains cancer-free more than 21 months later.
archTIS Ltd (ASX:AR9, OTCQB:ARHLF) reported continued momentum in the US defence market during the December 2025 quarter, with its NC Protect platform successfully deployed into a live Microsoft DoD365 production environment for the US Department of Defense.
During the period, the DoD’s systems integrator renewed 1,000 NC Protect production licences for a six-month term, moving the platform from pre-production evaluation into sustained operational use. archTIS also continued delivery of contracted development and integration services to support mission-specific capabilities within secure DoD365 environments, reinforcing its position within active defence workflows.
Solis Minerals Ltd (TSX-V:SLMN, ASX:SLM, OTCQB:SLMFF, FRA:08WA) has capped a busy December quarter with the acquisition of a large-scale copper porphyry system in Peru, steady drilling progress across its coastal exploration portfolio and a strengthened balance sheet to fund exploration through 2026.
The December 2025 quarterly report highlights the acquisition of the Cucho Copper Project, advancing drill programs at Ilo Este and Chancho al Palo, and the granting of drilling permits at Cinto, alongside a $5.9 million capital raise and completion of the company’s transition to the Australian market.
Sovereign Metals Ltd (ASX:SVM, OTC:SVMLF, AIM:SVML, FRA:SVM) has reported a pivotal December 2025 quarter marked by the recovery of high-value heavy rare earth elements from its flagship Kasiya Rutile-Graphite Project in Malawi — a development that could add a third revenue stream to the globally significant critical minerals project at minimal additional cost.
The company confirmed it has successfully recovered a monazite concentrate containing elevated levels of dysprosium, terbium and yttrium from the rutile tailings stream at Kasiya, with preliminary analysis showing heavy rare earth grades materially exceeding those of the world’s five largest rare earth producers.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has closed the December 2025 quarter with its lead oncology program HMBD-002 positioned to move into phase II testing, following the release of final phase I data and completion of detailed planning for the next stage of clinical development.
The quarter was marked by the presentation of full results from HMBD-002’s completed phase I study, confirmation of a favourable safety profile, and the release of a modular phase II trial design aimed at accelerating data read-outs across multiple tumour types.